BRAF and neoplasm: To analyze the potential association of a high tumor expression of the miR-99b~125a~let-7e cluster with clinical response to BRAF/MEKi treatment, we compared tumors excised pre-treatment from Long-term Responders (LR), i.e. patients which maintained treatment response for at least 2 years, and Short-term Responders (SR) from patients exhibiting a response duration of 6 months or less.